Form 20-F
TEVA PHARMACEUTICAL INDUSTRIES LTD filed this Form 20-F on 02/15/2017
Document Outline
Entire Document (10574.1 KB)
Subdocument 1 - 20-F - FORM 20-F
Page 1 - UNITED STATES
Page 2 - INDEX
Page 3 - N/A
Page 4 - INTRODUCTION AND USE OF CERTAIN TERMS
Page 5 - PART I
Page 6 - Operating Data
Page 7 - Dividends
Page 8 - RISK FACTORS
Page 9 - The increase in the number of competitors targeting generic opportunities and seeking U.S. market ex
Page 10 - We may be unable to take advantage of the increasing number of high-value biosimilar opportunities.
Page 11 - Investments in our pipeline of specialty and other products may not achieve expected results.
Page 12 - Our specialty pharmaceuticals business faces intense competition from companies that have greater re
Page 13 - Risks related to our substantially increased indebtedness
Page 14 - Additional risks related to our business and operations
Page 15 - Manufacturing or quality control problems may damage our reputation for quality production, demand c
Page 16 - The manufacture of our products is highly complex, and an interruption in our supply chain or proble
Page 17 - The failure to recruit or retain key personnel, including those who joined Teva as part of the Actav
Page 18 - We have significant operations in countries that may be adversely affected by political or economic
Page 19 - Compliance, regulatory and litigation risks
Page 20 - Governmental investigations into sales and marketing practices, particularly for our specialty pharm
Page 21 - We may be susceptible to significant product liability claims that are not covered by insurance.
Page 22 - Any failure to comply with the complex reporting and payment obligations under the Medicare and Medi
Page 23 - The large amount of long lived assets recorded on our balance sheet has significantly increased and
Page 24 - The termination or expiration of governmental programs or tax benefits, or a change in our business,
Page 25 - Introduction
Page 26 - N/A
Page 27 - Actavis Generics and Anda Acquisitions
Page 28 - Our Segments
Page 29 - OTC
Page 30 - APIs
Page 31 - Europe
Page 32 - Rest of the World Markets
Page 33 - Key market highlights
Page 34 - Specialty Medicines
Page 35 - Copaxone
Page 36 - Azilect
Page 37 - Laquinimod
Page 38 - Vantrela ER
Page 39 - TV-45070 Topical
Page 40 - QVAR
Page 41 - Respiratory Pipeline
Page 42 - Cinqair / Cinqaero
Page 43 - Oncology Pipeline
Page 44 - Plan B One-Step
Page 45 - Specialty
Page 46 - Operations
Page 47 - Raw Materials for Pharmaceutical Production
Page 48 - Environment, Health and Safety
Page 49 - Organizational Structure
Page 50 - Properties and Facilities
Page 51 - N/A
Page 52 - Regulation
Page 53 - N/A
Page 54 - N/A
Page 55 - Healthcare Reform and Certain Government Programs
Page 56 - European Union
Page 57 - Rest of the World Markets
Page 58 - Russia
Page 59 - Introduction
Page 60 - Highlights
Page 61 - N/A
Page 62 - Changes in Senior Management
Page 63 - Segment Information
Page 64 - United States Generic Medicines Revenues
Page 65 - Products.
Page 66 - N/A
Page 67 - Europe Generic Medicines Revenues
Page 68 - Comparison of 2015 to 2014.
Page 69 - ROW Generic Medicines Revenues
Page 70 - Generic Medicines Gross Profit
Page 71 - Comparison of 2015 to 2014
Page 72 - Specialty Medicines Revenues Breakdown
Page 73 - Comparison of 2015 to 2014.
Page 74 - Comparison of 2015 to 2014.
Page 75 - Comparison of 2015 to 2014
Page 76 - Comparison of 2015 to 2014
Page 77 - Comparison of 2015 to 2014.
Page 78 - Impairments, Restructuring and Others
Page 79 - Restructuring
Page 80 - Financial Expenses-Net
Page 81 - Share in (Profits) Losses of Associated Companies Net
Page 82 - Share Count for Market Capitalization
Page 83 - Liquidity and Capital Resources
Page 84 - N/A
Page 85 - 2016 Debt Movements
Page 86 - Shareholders Equity
Page 87 - Supplemental Non-GAAP Income Data
Page 88 - Investors should consider non-GAAP financial measures in addition to, and not as replacements for, o
Page 89 - N/A
Page 90 - N/A
Page 91 - N/A
Page 92 - Non-GAAP Effective Tax Rate
Page 93 - Trend Information
Page 94 - Critical Accounting Policies and Estimates
Page 95 - Rebates and Other Sales Reserves and Allowances:
Page 96 - Prompt Pay Discounts.
Page 97 - Income Taxes
Page 98 - Contingencies
Page 99 - Long Lived Assets
Page 100 - Acquisition of Actavis Generics and Anda
Page 101 - Assets held-for-sale
Page 102 - Directors and Senior Management
Page 103 - Directors
Page 104 - N/A
Page 105 - N/A
Page 106 - Directors
Page 107 - N/A
Page 108 - N/A
Page 109 - Compensation of Executive Officers and Directors
Page 110 - Aggregate Executive Compensation
Page 111 - Individual Covered Executive Compensation
Page 112 - N/A
Page 113 - N/A
Page 114 - N/A
Page 115 - N/A
Page 116 - Annual Cash Bonuses for 2016
Page 117 - 2010 Long-Term Equity-Based Incentive Plan
Page 118 - N/A
Page 119 - Performance Share Units
Page 120 - N/A
Page 121 - Director Remuneration for 2016
Page 122 - No-Hedging Policy; No-Pledging Policy; Stock Ownership Guidelines
Page 123 - Principles of Corporate Governance
Page 124 - Board Role in Risk Oversight
Page 125 - Committees of the Board
Page 126 - Human Resources and Compensation Committee
Page 127 - Science and Technology Committee
Page 128 - Major Shareholders
Page 129 - Consolidated Statements and Other Financial Information
Page 130 - ADSs
Page 131 - Memorandum and Articles of Association
Page 132 - Conflicts of Interest
Page 133 - Approval of Director and Executive Officer Compensation
Page 134 - Dividends
Page 135 - Voting and Quorum Requirements
Page 136 - Description of Mandatory Convertible Preferred Shares
Page 137 - Ownership and Voting of Teva Shares
Page 138 - Taxation of Distributions to U.S. Holders
Page 139 - Taxation of the Disposition of ADSs
Page 140 - Israeli Taxation Applicable to Holders of Our Ordinary Shares, Mandatory Convertible Preferred Share
Page 141 - Law for the Encouragement of Industry (Taxes), 1969 (the Industry Encouragement Law )
Page 142 - The New Technological Enterprise Incentives Regime Amendment 73 to the Investment Law
Page 143 - Documents on Display
Page 144 - Exchange Rate Risk Management
Page 145 - Interest Rate Risk Management
Page 146 - Fees and Charges Payable by ADS Holders
Page 147 - Fees Payable by the Depositary to Teva
Page 148 - at http://www.tevapharm.com
Page 149 - Policy on Pre-Approval of Audit and Non-Audit Services of Independent Auditors
Page 150 - PART III
Page 151 - N/A
Page 152 - N/A
Page 153 - N/A
Page 154 - N/A
Page 155 - SIGNATURES
Page 156 - TEVA PHARMACEUTICAL INDUSTRIES LIMITED
Page 157 - REPORT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM
Page 158 - N/A
Page 159 - TEVA PHARMACEUTICAL INDUSTRIES LIMITED
Page 160 - TEVA PHARMACEUTICAL INDUSTRIES LIMITED
Page 161 - TEVA PHARMACEUTICAL INDUSTRIES LIMITED
Page 162 - TEVA PHARMACEUTICAL INDUSTRIES LIMITED
Page 163 - TEVA PHARMACEUTICAL INDUSTRIES LIMITED
Page 164 - TEVA PHARMACEUTICAL INDUSTRIES LIMITED
Page 165 - TEVA PHARMACEUTICAL INDUSTRIES LIMITED
Page 166 - TEVA PHARMACEUTICAL INDUSTRIES LIMITED
Page 167 - TEVA PHARMACEUTICAL INDUSTRIES LIMITED
Page 168 - TEVA PHARMACEUTICAL INDUSTRIES LIMITED
Page 169 - TEVA PHARMACEUTICAL INDUSTRIES LIMITED
Page 170 - TEVA PHARMACEUTICAL INDUSTRIES LIMITED
Page 171 - TEVA PHARMACEUTICAL INDUSTRIES LIMITED
Page 172 - TEVA PHARMACEUTICAL INDUSTRIES LIMITED
Page 173 - TEVA PHARMACEUTICAL INDUSTRIES LIMITED
Page 174 - TEVA PHARMACEUTICAL INDUSTRIES LIMITED
Page 175 - TEVA PHARMACEUTICAL INDUSTRIES LIMITED
Page 176 - TEVA PHARMACEUTICAL INDUSTRIES LIMITED
Page 177 - TEVA PHARMACEUTICAL INDUSTRIES LIMITED
Page 178 - TEVA PHARMACEUTICAL INDUSTRIES LIMITED
Page 179 - TEVA PHARMACEUTICAL INDUSTRIES LIMITED
Page 180 - TEVA PHARMACEUTICAL INDUSTRIES LIMITED
Page 181 - TEVA PHARMACEUTICAL INDUSTRIES LIMITED
Page 182 - TEVA PHARMACEUTICAL INDUSTRIES LIMITED
Page 183 - TEVA PHARMACEUTICAL INDUSTRIES LIMITED
Page 184 - TEVA PHARMACEUTICAL INDUSTRIES LIMITED
Page 185 - TEVA PHARMACEUTICAL INDUSTRIES LIMITED
Page 186 - TEVA PHARMACEUTICAL INDUSTRIES LIMITED
Page 187 - TEVA PHARMACEUTICAL INDUSTRIES LIMITED
Page 188 - TEVA PHARMACEUTICAL INDUSTRIES LIMITED
Page 189 - TEVA PHARMACEUTICAL INDUSTRIES LIMITED
Page 190 - TEVA PHARMACEUTICAL INDUSTRIES LIMITED
Page 191 - TEVA PHARMACEUTICAL INDUSTRIES LIMITED
Page 192 - TEVA PHARMACEUTICAL INDUSTRIES LIMITED
Page 193 - TEVA PHARMACEUTICAL INDUSTRIES LIMITED
Page 194 - TEVA PHARMACEUTICAL INDUSTRIES LIMITED
Page 195 - TEVA PHARMACEUTICAL INDUSTRIES LIMITED
Page 196 - TEVA PHARMACEUTICAL INDUSTRIES LIMITED
Page 197 - TEVA PHARMACEUTICAL INDUSTRIES LIMITED
Page 198 - TEVA PHARMACEUTICAL INDUSTRIES LIMITED
Page 199 - TEVA PHARMACEUTICAL INDUSTRIES LIMITED
Page 200 - TEVA PHARMACEUTICAL INDUSTRIES LIMITED
Page 201 - TEVA PHARMACEUTICAL INDUSTRIES LIMITED
Page 202 - TEVA PHARMACEUTICAL INDUSTRIES LIMITED
Page 203 - TEVA PHARMACEUTICAL INDUSTRIES LIMITED
Page 204 - TEVA PHARMACEUTICAL INDUSTRIES LIMITED
Page 205 - TEVA PHARMACEUTICAL INDUSTRIES LIMITED
Page 206 - TEVA PHARMACEUTICAL INDUSTRIES LIMITED
Page 207 - TEVA PHARMACEUTICAL INDUSTRIES LIMITED
Page 208 - TEVA PHARMACEUTICAL INDUSTRIES LIMITED
Page 209 - TEVA PHARMACEUTICAL INDUSTRIES LIMITED
Page 210 - TEVA PHARMACEUTICAL INDUSTRIES LIMITED
Page 211 - TEVA PHARMACEUTICAL INDUSTRIES LIMITED
Page 212 - TEVA PHARMACEUTICAL INDUSTRIES LIMITED
Page 213 - TEVA PHARMACEUTICAL INDUSTRIES LIMITED
Page 214 - TEVA PHARMACEUTICAL INDUSTRIES LIMITED
Page 215 - TEVA PHARMACEUTICAL INDUSTRIES LIMITED
Page 216 - TEVA PHARMACEUTICAL INDUSTRIES LIMITED
Page 217 - TEVA PHARMACEUTICAL INDUSTRIES LIMITED
Page 218 - TEVA PHARMACEUTICAL INDUSTRIES LIMITED
Page 219 - TEVA PHARMACEUTICAL INDUSTRIES LIMITED
Page 220 - TEVA PHARMACEUTICAL INDUSTRIES LIMITED
Page 221 - TEVA PHARMACEUTICAL INDUSTRIES LIMITED
Page 222 - TEVA PHARMACEUTICAL INDUSTRIES LIMITED
Page 223 - TEVA PHARMACEUTICAL INDUSTRIES LIMITED
Page 224 - TEVA PHARMACEUTICAL INDUSTRIES LIMITED
Page 225 - TEVA PHARMACEUTICAL INDUSTRIES LIMITED
Page 226 - TEVA PHARMACEUTICAL INDUSTRIES LIMITED
Page 227 - TEVA PHARMACEUTICAL INDUSTRIES LIMITED
Page 228 - TEVA PHARMACEUTICAL INDUSTRIES LIMITED
Page 229 - TEVA PHARMACEUTICAL INDUSTRIES LIMITED
Page 230 - TEVA PHARMACEUTICAL INDUSTRIES LIMITED
Page 231 - TEVA PHARMACEUTICAL INDUSTRIES LIMITED
Page 232 - TEVA PHARMACEUTICAL INDUSTRIES LIMITED
Page 233 - TEVA PHARMACEUTICAL INDUSTRIES LIMITED
Page 234 - TEVA PHARMACEUTICAL INDUSTRIES LIMITED
Page 235 - TEVA PHARMACEUTICAL INDUSTRIES LIMITED
Page 236 - TEVA PHARMACEUTICAL INDUSTRIES LIMITED
Page 237 - Report of Independent Registered Public Accounting Firm on Financial Statement Schedule
Page 238 - TEVA PHARMACEUTICAL INDUSTRIES LIMITED
Subdocument 2 - EX-8 - EX-8
Page 1 - Exhibit 8
Subdocument 3 - EX-10 - EX-10
Page 1 - Exhibit 10
Subdocument 4 - EX-12.(I) - EX-12.(I)
Page 1 - Exhibit 12(i)
Subdocument 5 - EX-12.(II) - EX-12.(II)
Page 1 - Exhibit 12(ii)
Subdocument 6 - EX-13 - EX-13
Page 1 - Exhibit 13
XBRL Item - EX-101.INS - XBRL INSTANCE DOCUMENT (What's this?)
XBRL Item - EX-101.SCH - XBRL TAXONOMY EXTENSION SCHEMA (What's this?)
XBRL Item - EX-101.CAL - XBRL TAXONOMY EXTENSION CALCULATION LINKBASE (What's this?)
XBRL Item - EX-101.DEF - XBRL TAXONOMY EXTENSION DEFINITION LINKBASE (What's this?)
XBRL Item - EX-101.LAB - XBRL TAXONOMY EXTENSION LABEL LINKBASE (What's this?)
XBRL Item - EX-101.PRE - XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE (What's this?)
XBRL Viewer